Subscribe
piotr-zajda-shutterstock-com
Piotr Zajda / Shutterstock.com
30 November 2015Americas

Nautilus’s Supreme Court petition bolstered by tech companies’ support

A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
US Supreme Court knocks back two medical device disputes
1 December 2015   The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech